Opthea Limited ( (AU:OPT) ) has shared an update.
Opthea Limited has requested a voluntary suspension of its securities from trading on the ASX pending the announcement of results from its Phase 3 COAST clinical trial. This suspension is intended to maintain market stability until the company can release the top line results, which are expected to have significant implications for its operations and market positioning.
More about Opthea Limited
Opthea Limited operates in the biotechnology industry, focusing on the development of therapies for eye diseases. The company’s primary product is OPT-302, which is being evaluated in combination with Aflibercept in clinical trials for the treatment of wet age-related macular degeneration.
YTD Price Performance: 9.09%
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $471.5M
Learn more about OPT stock on TipRanks’ Stock Analysis page.